GLP-1 receptor agonists liraglutide and semaglutide: Liraglutide and semaglutide are examples of GLP-1 receptor agonists which are antidiabetic agents that have been established as effective antidiabetic interventions in MASH owing to their interventional impacts in weight regression, insulin sensitivity, and hepatic metabolism. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.